Verona Pharma Plc, a clinical-stage British company developing treatments for respiratory diseases, has announced plans to delist its shares from the AIM market in London portion of the London Stock Exchange on 30 October because a parallel listing on the US Nasdaq market has accounted for 98% of trading in the past six months.
Shareholders who convert their shares into American Depository Shares (ADSs) prior to the delisting will not be subject to stamp duty or charges by the depository bank, the company said.
